Medigen Vaccine Biologics (TWO:6547) — Market Cap & Net Worth
Market Cap & Net Worth: Medigen Vaccine Biologics (6547)
Medigen Vaccine Biologics (TWO:6547) has a market capitalization of $619.37 Million (NT$19.66 Billion) as of September 28, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #11235 globally and #401 in its home market, demonstrating a -1.16% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medigen Vaccine Biologics's stock price NT$59.80 by its total outstanding shares 328749000 (328.75 Million). Also see total assets of Medigen Vaccine Biologics for a full breakdown of the balance sheet.
Medigen Vaccine Biologics Market Cap History: 2015 to 2026
Medigen Vaccine Biologics's market capitalization history from 2015 to 2026. Data shows growth from $216.82 Million to $619.37 Million (12.04% CAGR). Also see Medigen Vaccine Biologics (6547) cash conversion ratio for how efficiently the company converts equity into cash flow.
Medigen Vaccine Biologics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medigen Vaccine Biologics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Medigen Vaccine Biologics share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.64x
Medigen Vaccine Biologics's market cap is 0.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $194.30 Million | $1.12 Million | -$636.84 Million | 173.48x | N/A |
| 2020 | $716.84 Million | $11.51 Million | -$690.70 Million | 62.30x | N/A |
| 2021 | $2.08 Billion | $3.28 Billion | $1.41 Billion | 0.63x | 1.48x |
| 2022 | $719.84 Million | $365.04 Million | -$1.50 Billion | 1.97x | N/A |
| 2023 | $726.05 Million | $389.62 Million | -$1.16 Billion | 1.86x | N/A |
| 2024 | $373.38 Million | $605.64 Million | -$80.47 Million | 0.62x | N/A |
| 2025 | $390.99 Million | $613.17 Million | -$281.71 Million | 0.64x | N/A |
Competitor Companies of 6547 by Market Capitalization
Companies near Medigen Vaccine Biologics in the global market cap rankings as of September 28, 2026. Review Medigen Vaccine Biologics (6547) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Medigen Vaccine Biologics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #339 globally with a market cap of $79.70 Billion USD.
- CSL Ltd (AU:CSL): Ranked #453 globally with a market cap of $60.74 Billion USD ( AU$85.85 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #507 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $526.19 |
| #339 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.70 Billion | $788.04 |
| #453 | CSL Ltd | AU:CSL | $60.74 Billion | AU$176.95 |
| #507 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $198.88 |
Medigen Vaccine Biologics Historical Marketcap From 2015 to 2026
Between 2015 and today, Medigen Vaccine Biologics's market cap moved from $216.82 Million to $ 619.37 Million, with a yearly change of 12.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$619.37 Million | +58.41% |
| 2025 | NT$390.99 Million | +4.72% |
| 2024 | NT$373.38 Million | -48.57% |
| 2023 | NT$726.05 Million | +0.86% |
| 2022 | NT$719.84 Million | -65.41% |
| 2021 | NT$2.08 Billion | +190.29% |
| 2020 | NT$716.84 Million | +268.94% |
| 2019 | NT$194.30 Million | -17.88% |
| 2018 | NT$236.60 Million | +29.25% |
| 2017 | NT$183.06 Million | -10.79% |
| 2016 | NT$205.20 Million | -5.36% |
| 2015 | NT$216.82 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 28th, 2026 the market cap of Medigen Vaccine Biologics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $619.37 Million USD |
| MoneyControl | $619.37 Million USD |
| MarketWatch | $619.37 Million USD |
| marketcap.company | $619.37 Million USD |
| Reuters | $619.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more